Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Second US pivotal phase III, randomised, double-blind, placebo-controlled trial investigating the efficacy and safety of topical alprostadil in patients with mild to severe erectile dysfunction

X
Trial Profile

Second US pivotal phase III, randomised, double-blind, placebo-controlled trial investigating the efficacy and safety of topical alprostadil in patients with mild to severe erectile dysfunction

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 02 Apr 2018

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Alprostadil (Primary)
  • Indications Erectile dysfunction
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 26 Mar 2018 According to an Apricus Biosciences media release, end-of-review meeting with the U.S. Food and Drug Administration (FDA) to discuss the New Drug Application for Vitaros for the treatment of erectile dysfunction, is now scheduled to be held on April 12, 2018.
    • 31 Aug 2017 According to an Apricus Biosciences media release, the company announces that the U. S. Food and Drug Application has acknowledged receipt its resubmitted NDA for Vitaros (alprostadil, DDAIP.HCI ) and considers it a complete, class 2 response to Apricus 2008 action letter. The PDUFA (Prescription Drug User Fee Act) goal date for completion of FDA's review of Vitaros NDA is set for 17 Feb 2018, which is the standard six-month review period for NDA resubmission.
    • 29 Aug 2017 According to an Apricus Biosciences media release, the company recently filed its resubmission of a New Drug Application (NDA) for Vitaros (alprostadil, DDAIP.HCl) with the U.S. Food and Drug Administration (FDA). Apricus anticipates a six-month review by the FDA with a projected PDUFA (Prescription Drug User Fee Act) goal date in the first quarter of 2018, which it expects the FDA to acknowledge within 30 days of the NDA filing date.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top